Nurix Therapeutics Inc (NASDAQ:NRIX) price on current trading day, rose 3.67% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $9.60.
A look at the stock’s price movement, the close in the last trading session was $9.26, moving within a range at $8.56 and $10.16. The beta value (5-Year monthly) was 2.236. Turning to its 52-week performance, $29.56 and $8.60 were the 52-week high and 52-week low respectively. Overall, NRIX moved -30.94% over the past month.
Nurix Therapeutics Inc’s market cap currently stands at around $731.86 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Apr-07.
The average forecast suggests up to a 35.26% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 62.09M, representing a 13.83% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NRIX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
16 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 13 recommend NRIX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NRIX’s current price about -20.33% and -35.49% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 28.32, while 7-day volatility ratio is 13.59% and 8.52% in the 30-day chart. Further, Nurix Therapeutics Inc (NRIX) has a beta value of 2.20, and an average true range (ATR) of 1.05. Analysts have given the company’s stock an average 52-week price target of $34, forecast between a low of $16 and high of $41. Looking at the price targets, the low is -66.67% off current price level while to achieve the yearly target high, price needs to move -327.08%. Nonetheless, investors will most likely welcome a -254.17% jump to $34 which is the analysts’ median price.
If we refocus on Nurix Therapeutics Inc (NASDAQ:NRIX), historical trading data shows that trading volumes averaged 1.37 over the past 10 days and 869.40K over the past 3 months. The company’s latest data on shares outstanding shows there are 76.23 million shares.
The 1.99% of Nurix Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 107.70% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 12.17 million on 2025-03-14, giving us a short ratio of 14.75. The data shows that as of 2025-03-14 short interest in Nurix Therapeutics Inc (NRIX) stood at 1711.9999999999998 of shares outstanding, with shares short rising to 11.36 million registered in 2025-02-14. Current price change has pushed the stock -49.04% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NRIX stock continues to rise going into the next quarter.
